AI Article Synopsis

  • The study analyzed 54 breast cancer patients who experienced local recurrence, treated at Greatpoland Cancer Center from 1983 to 1995, making up 6.2% of all breast cancer patients treated during that time.
  • It found that the median time from the first diagnosis to recurrence was approximately 26.6 months, with variations in initial tumor stages and treatment methods affecting prognosis.
  • The overall 5-year survival rate for these patients was 33.3%; survival varied significantly based on the time interval between the first diagnosis and recurrence, with shorter intervals correlating to poorer survival rates.

Article Abstract

The study was made to evaluate the clinical and pathological features of breast cancer patients with locally recurrent breast cancer and to assess the impact of the treatment method on their prognosis. Fifty-four patients with local recurrence after breast cancer were treated in Greatpoland Cancer Center between 1983 and 1995. It constituted 6.2% (54/878) of all patients with breast cancer treated in this period. Median length of interval between primary lesion and recurrence was 26.6 months, in 12/54 cases (22.2%) was longer then 5 years. Patients in time of recognizing primary breast cancer had tumor in clinical stage T2 (n=25) and T3 or T4 (n=29), in stage N0 (n=16) and N1 (n=36). Patients with recurrent breast cancer were treated using different methods. In 26 cases recurrent tumor was excited and then, in 15 cases irradiated, in 11 cases irradiated and additionally treated by chemotherapy or by hormonotherapy. In 28 cases patients were disqualified for excision due to local advance of disease. They were all irradiated and then treated by chemotherapy (n=17) or hormonotherapy (n=11). 5-year survival rates were compared with the chosen clinical factors (age, clinical stage, histopathology), length of interval between primary tumor and recurrence and with different methods of treatment including excision or not. 5-year overall survival rate was 33.3%. In locally advanced tumors (stage T3) the effect was worse then in stage T2 tumors. Five-year survival rates after recurrence were 20.8% and 52.0%, respectively (p=0.001). No statistically important correlations between lymph node involvement, age, histology and survival rate were found. Differences between 5-year survival rate were observed according to length of interval between recognizing the primary lesion and recurrence. Patients with interval shorter then 24 months had survival rate 14.3%, between 24 and 60 months - survival rate 64.3% and with interval longer then 60 months - 41.7%. Statistically important differences were noted between first and second group (p=0.01) and first and third group (p=0.03). Patients treated with local excision followed by radiotherapy and/or systemic therapy had greater 5-year survival rate (53.9%) then patients disqualified for incision (14.3%) (p=0.0001).

Download full-text PDF

Source

Publication Analysis

Top Keywords

breast cancer
28
survival rate
24
5-year survival
16
cancer treated
12
length interval
12
patients
9
recurrence breast
8
cancer
8
recurrent breast
8
interval primary
8

Similar Publications

Purpose: To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for early breast cancer (BC).

Methods: Individual patient data of neoadjuvant RCTs with available data on pCR, iDFS, and OS were included in the analysis. We used the coefficient of determination from weighted linear regression models to quantify the association between treatment effects on OS and on the surrogate end points.

View Article and Find Full Text PDF

Breast and cervical cancers are the most prevalent diagnosed in women worldwide, significantly contributing to maternal morbidity and mortality. We examined socio-demographic and behavioral factors associated with breast and cervical cancer screening among Cambodian women aged 15-49 years old. We analyzed women's data from the 2022 Cambodia Demographic and Health Survey (CDHS).

View Article and Find Full Text PDF

Background: Cancer patients have up to a 3-fold higher risk for cardiovascular disease (CVD) than the general population. Traditional CVD risk scores may be less accurate for them. We aimed to develop cancer-specific CVD risk scores and compare them with conventional scores in predicting 10-year CVD risk for patients with breast cancer (BC), colorectal cancer (CRC), or lung cancer (LC).

View Article and Find Full Text PDF

Chitosan-Functionalized Fluorescent Calcium Carbonate Nanoparticle Loaded with Methotrexate: Future Theranostics for Triple Negative Breast Cancer.

ACS Biomater Sci Eng

January 2025

Nano 2 Micro Material Design Lab, Department of Chemical Engineering and Technology, IIT (BHU), Varanasi 221005, India.

Herein, fluorescent calcium carbonate nanoclusters encapsulated with methotrexate (Mtx) and surface functionalized with chitosan (25 nm) (@Calmat) have been developed for the imaging and treatment of triple-negative breast cancer (TNBC). These biocompatible, pH-sensitive nanoparticles demonstrate significant potential for targeted therapy and diagnostic applications. The efficacy of nanoparticles (NPs) was evaluated in MDA-MB-231 TNBC cell lines.

View Article and Find Full Text PDF

Antiproliferative activity of a series of copper(II) complexes derived from a furan-containing -acylhydrazone: monomers, dimers, charge status, and cell mechanistic studies on triple negative breast cancer cells.

Dalton Trans

January 2025

CEQUINOR (UNLP, CCT-CONICET La Plata, asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Blvd. 120 No. 1465, La Plata (1900), Argentina.

In this work, we evaluated the anticancer activity of compounds 1 (mononuclear) and 2 (dinuclear) copper(II) coordination compounds derived from the ligand 5-methylsalicylaldehyde 2-furoyl hydrazone (H2L) over MDA-MB-231 Triple-negative breast cancer (TNBC) cells, and compared their activities with that of a newly synthesized, protonated, dinuclear analogue of 2 (complex 3). Here, we report the synthesis of compound 3 and it has been characterized in the solid state (X-ray diffraction, FTIR) and in solution (EPR, UV-Vis, ESI) as well as its electrochemical profile. Complexes 1-3 impaired cell viability from 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!